Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
The intensity of the color is positively correlated with the amount of semaphorin-3B (SEMA3B) in the sample
usually indicating diabetes
and anti-detachment slides are used
Pour the mixture into a glass homogenizer and grind thoroughly on ice
ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Biology Kits The intensity of the colorProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat
US$ 227.20
US$ 286.40
US$ 227.20
US$ 227.20
US$ 227.20
US$ 286.40
US$ 276.80
US$ 304.00
US$ 313.60
US$ 324.80